National and Kapodistrian University of Athens
Τc-99m depreotide: διάγνωση, σταδιοποίηση και παρακολούθηση ασθενών με καρκίνο πνεύμονος
Abstract
dc:description99mTc-depreotide is a small synthetic decapeptide labelled somatostatin analogue, which has the ability to bind selectively to 2, 3 and 5 subtypes of somatostatin receptors (SSTRs). SSTRs are upregulated in malignant tumors including small cell, and non-small cell lung cancer.The aim of the present thesis was to assess the clinical value of somatostatin receptor scintigraphy with 99mTc-depreotide in patients with lung cancer a) preoperative for diagnosis and staging b) post-therapeutic of any disease relapse. We studied 123 patients, 101 men and 22 women of median age 63.2 years (range 38 - 90 years) who were classified into 2 groups.In the first group, 79 patients tested preoperatively for diagnosis and staging of disease and in the second group 44 patients with known primary lung cancer after initial treatment were assessed for disease recurrence. All patients underwent 99mTc-depreotide whole-body scan and SPECT imaging of the thorax. Fifty seven out of 79 patients from the first group, had histological findings consistent with malignancy (72.2%) and 22 (27.8%) revealed benign pulmonary lesions. Fifty-five of 57 (96.5%) were correctly identified as positive and 16/22 (72.7%) as negative with 99mTc-depreotide scintigraphy. The positive predictive value, negative predictive value and overall diagnostic accuracy of 99mTc-depreotide were 90.1%, 88.9% and 89.9% respectively. The pathological investigation of 48 patients with primary lung cancer after mediastinoscopy or thoracotomy revealed metastases in mediastinal lymph nodes in 23 patients whereas 25 were free of disease. When 99mTc-depreotide stage was compared with histopathologic stage, the disease in 21 (91.3%) patients was accurately staged. Τhere was a statistically significant difference in the diagnostic accuracy for 99mTc-depreotide SPECT imaging in staging of lung cancer 91.6% versus chest CT 66.7% (p<0,05). Preoperative staging with 99mTc-depreotide whole body imaging revealed unexpected distant metastases in six (12.5%) patients (4 patients with bone and 2 with brain metastases). Twenty - six of 44 patients (50.1%) of the second group, had confirmed disease recurrence and 18 (40.9%) had no evidence of disease. 99mTc-depreotide correctly diagnosed recurrence in all 26/26 patients (100%) and provided true negative findings in 15/18 (83.3%) who had no evidence of recurrence. The positive predictive value, negative predictive value and diagnostic accuracy of 99mTc-depreotide in the prediction of lung cancer relapse were 89,6%, 100% and 93,2%, respectively.In conclusion, the results of the present study suggest that 99mTc-depreotide has a diagnostic ability in distinguishing malignant from benign lung lesions, in the initial staging of non-small cell lung cancer, enables early detection of intrathoracic or extrathoracic metastases and after initial treatment shows high capability to detect residual or recurrent disease.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Iordanidou, Lydia
- Ιορδανίδου, Λυδία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41499